These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Low Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB. Lee SH; Seo KA; Lee YM; Lee HK; Kim JH; Shin C; Ghim JR; Shin JG; Kim DH Yonsei Med J; 2015 Jul; 56(4):961-7. PubMed ID: 26069117 [TBL] [Abstract][Full Text] [Related]
5. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Yew WW; Chan CK; Chau CH; Tam CM; Leung CC; Wong PC; Lee J Chest; 2000 Mar; 117(3):744-51. PubMed ID: 10713001 [TBL] [Abstract][Full Text] [Related]
6. Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis. Lee H; Ahn S; Hwang NY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Kim CK; Koh WJ Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203478 [TBL] [Abstract][Full Text] [Related]
7. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076 [TBL] [Abstract][Full Text] [Related]
8. Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection. Al-Shaer MH; Alghamdi WA; Alsultan A; An G; Ahmed S; Alkabab Y; Banu S; Barbakadze K; Houpt E; Kipiani M; Mikiashvili L; Cegielski JP; Kempker RR; Heysell SK; Peloquin CA Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061152 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. Prasad R; Verma SK; Sahai S; Kumar S; Jain A Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study. Heysell SK; Mpagama SG; Ogarkov OB; Conaway M; Ahmed S; Zhdanova S; Pholwat S; Alshaer MH; Chongolo AM; Mujaga B; Sariko M; Saba S; Rahman SMM; Uddin MKM; Suzdalnitsky A; Moiseeva E; Zorkaltseva E; Koshcheyev M; Vitko S; Mmbaga BT; Kibiki GS; Pasipanodya JG; Peloquin CA; Banu S; Houpt ER Clin Infect Dis; 2023 Feb; 76(3):497-505. PubMed ID: 35731948 [TBL] [Abstract][Full Text] [Related]
11. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis. Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570 [TBL] [Abstract][Full Text] [Related]
12. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149 [TBL] [Abstract][Full Text] [Related]
13. Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania. Mpagama SG; Houpt ER; Stroup S; Kumburu H; Gratz J; Kibiki GS; Heysell SK BMC Infect Dis; 2013 Sep; 13():432. PubMed ID: 24034230 [TBL] [Abstract][Full Text] [Related]
14. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. Bouton TC; Phillips PPJ; Mitnick CD; Peloquin CA; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Horsburgh CR Trials; 2017 Nov; 18(1):563. PubMed ID: 29178937 [TBL] [Abstract][Full Text] [Related]
15. Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay. Trollip AP; Moore D; Coronel J; Caviedes L; Klages S; Victor T; Romancenco E; Crudu V; Ajbani K; Vineet VP; Rodrigues C; Jackson RL; Eisenach K; Garfein RS; Rodwell TC; Desmond E; Groessl EJ; Ganiats TG; Catanzaro A Int J Tuberc Lung Dis; 2014 Feb; 18(2):227-32. PubMed ID: 24429318 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients: preliminary results. Singla R; Gupta S; Gupta R; Arora VK Int J Tuberc Lung Dis; 2001 Jun; 5(6):559-63. PubMed ID: 11409584 [TBL] [Abstract][Full Text] [Related]
17. Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients. Modongo C; Pasipanodya JG; Magazi BT; Srivastava S; Zetola NM; Williams SM; Sirugo G; Gumbo T Antimicrob Agents Chemother; 2016 Oct; 60(10):5928-32. PubMed ID: 27458224 [TBL] [Abstract][Full Text] [Related]
18. Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China. Zheng X; Zheng R; Hu Y; Werngren J; Forsman LD; Mansjö M; Xu B; Hoffner S Antimicrob Agents Chemother; 2016 Aug; 60(8):4786-92. PubMed ID: 27246779 [TBL] [Abstract][Full Text] [Related]
19. Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis. Deshpande D; Pasipanodya JG; Mpagama SG; Srivastava S; Bendet P; Koeuth T; Lee PS; Heysell SK; Gumbo T Clin Infect Dis; 2018 Nov; 67(suppl_3):S317-S326. PubMed ID: 30496457 [TBL] [Abstract][Full Text] [Related]
20. Validation of Cycloserine Efficacy in Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Beijing, China. Yu X; Zeng X; Shi W; Hu Y; Nie W; Chu N; Huang H Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311073 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]